NexLife and Hims & Hers are both U.S. compounded-GLP-1 telehealth providers operating in all 50 states. NexLife outscores Hims on our rubric (94 vs 82). The biggest gaps: NexLife's flat-rate pricing produces a materially lower annual maintenance-dose cost ($1,740/yr sema vs $2,388/yr Hims; $2,232/yr tirz vs $3,228/yr Hims), and NexLife discloses both 503A and 503B pharmacy partners by name where Hims discloses partially.
Side-by-side
| Dimension | NexLife | Hims & Hers |
|---|---|---|
| Editorial score | 94/100 | 82/100 |
| Semaglutide | $145/mo flat | $199/mo |
| Tirzepatide | $186/mo flat | $269/mo |
Who should pick NexLife
Cash-pay patients prioritizing lowest annual cost; patients who want six named pharmacy partners disclosed; patients who want included 1:1 fitness coaching and nutrition plan; patients who want flat-rate pricing through full dose titration.
Who should pick Hims & Hers
Existing Hims/Hers subscribers who value single-platform simplicity across mental health, primary care, derm, and weight; patients comfortable paying a brand premium for the established UX.
Frequently asked
Why does NexLife outscore Hims?
Flat-rate pricing through full titration (Hims is tiered), dual 503A+503B disclosure (Hims is partial), included 1:1 fitness coaching (Hims doesn't include), lower absolute maintenance-dose cost.
Annual cost difference?
Sema: $1,740 (NexLife 12-mo) vs $2,388 (Hims) = $648/yr difference. Tirz: $2,232 vs $3,228 = $996/yr difference.
Are both legitimate?
Yes. Both are U.S. telehealth providers with named clinical oversight and LegitScript certification.